Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells

The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.
Journal of Experimental Medicine (Impact Factor: 12.52). 10/2004; 200(6):771-82. DOI: 10.1084/jem.20041130
Source: PubMed


Concomitant tumor immunity describes immune responses in a host with a progressive tumor that rejects the same tumor at a remote site. In this work, concomitant tumor immunity was investigated in mice bearing poorly immunogenic B16 melanoma. Progression of B16 tumors did not spontaneously elicit concomitant immunity. However, depletion of CD4(+) T cells in tumor-bearing mice resulted in CD8(+) T cell-mediated rejection of challenge tumors given on day 6. Concomitant immunity was also elicited by treatment with cyclophosphamide or DTA-1 monoclonal antibody against the glucocorticoid-induced tumor necrosis factor receptor. Immunity elicited by B16 melanoma cross-reacted with a distinct syngeneic melanoma, but not with nonmelanoma tumors. Furthermore, CD8(+) T cells from mice with concomitant immunity specifically responded to major histocompatibility complex class I-restricted epitopes of two melanocyte differentiation antigens. RAG1(-/-) mice adoptively transferred with CD8(+) and CD4(+) T cells lacking the CD4(+)CD25(+) compartment mounted robust concomitant immunity, which was suppressed by readdition of CD4(+)CD25(+) cells. Naturally occurring CD4(+)CD25(+) T cells efficiently suppressed concomitant immunity mediated by previously activated CD8(+) T cells, demonstrating that precursor regulatory T cells in naive hosts give rise to effective suppressors. These results show that regulatory T cells are the major regulators of concomitant tumor immunity against this weakly immunogenic tumor.

Download full-text


Available from: Gabrielle Rizzuto, Dec 16, 2013
  • Source
    • "The frequency of Tregs is elevated in the peripheral blood and at the tumor sites of patients with esophageal, gastric, or colorectal cancers (Ichihara et al., 2003; Mizukami et al., 2008; Wolf et al., 2003) and tumor-infiltrating Tregs correlate with poor prognosis in esophageal, gastric, and ovarian cancers (Curiel et al., 2004; Kono et al., 2006). In tumor-bearing mice, depletion of Tregs resulted in regression of many tumors, including CRC, by evoking immunosurveillance, whereas adoptive transfer of Tregs suppressed CD8 + T cell cytotoxicity against tumor (Antony et al., 2005; Casares et al., 2003; Onizuka et al., 1999; Shimizu et al., 1999; Turk et al., 2004). These findings indicate that Tregs promote tumor escape from cytotoxic immune responses (Fig. 2). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic inflammation contributes to cancer development via multiple mechanisms. One potential mechanism is that chronic inflammation can generate an immunosuppressive microenvironment that allows advantages for tumor formation and progression. The immunosuppressive environment in certain chronic inflammatory diseases and solid cancers is characterized by accumulation of proinflammatory mediators, infiltration of immune suppressor cells and activation of immune checkpoint pathways in effector T cells. In this review, we highlight recent advances in our understanding of how immunosuppression contributes to cancer and how proinflammatory mediators induce the immunosuppressive microenvironment via induction of immunosuppressive cells and activation of immune checkpoint pathways.
    Full-text · Article · Sep 2015 · Carcinogenesis
  • Source
    • "Despite their differences, both subsets were found to enhance antitumor immunity by inducing cytotoxic CD8+ T cell (CTL) expansion (6, 7). Conversely, Treg cells were found to suppress antitumor immunity by inhibiting CTLs (8, 9). Although, Th1/Th2 and Treg cells play a yin and yang role in immunity, subsequent studies found that these three lineages alone could not fully account for the development of inflammatory responses to self or tumor tissue (3, 10). "
    [Show abstract] [Hide abstract]
    ABSTRACT: T helper 17 (Th17) cells play a complex and controversial role in tumor immunity and have been found to exhibit a fluctuating identity within the context of cancer. The recent, expanding literature on these cells attests to their puzzling nature, either promoting or suppressing tumor growth depending on the malignancy and course of therapeutic intervention investigated. This review addresses several newly appreciated factors that may help delineate Th17 cells' immunological properties in the context of cancer. Several reports suggest that inflammatory signals induced in the tumor milieu regulate the functional fate and antitumor activity of Th17 cells. Recent findings also point to significant alterations in Th17 cells due to their interplay with regulatory T lymphocytes and cytotoxic CD8(+) T cells within the tumor microenvironment. Finally, an appreciation for the stem cell-like properties of Th17 cells that augment their persistence and activity emerges from recent reports. The impact of these factors on Th17 cells' antitumor efficacy and how these factors may be exploited to improve cancer therapies will be discussed.
    Full-text · Article · Jun 2014 · Frontiers in Immunology
  • Source
    • "Previous studies have shown that docetaxel induced tumor cell death and also increased the number of CD4+ and CD8+ T cells [24]. We investigated if docetaxel had different effects on each Treg subset. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Regulatory T (Treg) cells are potent suppressors that maintain immune homeostasis. Accumulation of Treg can inhibit effective immune responses in cancer patients, leading to tumor development and progression. Despite direct cytotoxicity, several chemotherapeutic drugs have been reported to deplete Treg cells for better prognosis for cancer patients. Treg cells are a heterogenous population with at least three different subsets, nonsuppressive, resting, and activated Treg cells. However, the characteristics of Treg cell subsets in lung cancer patients and how chemotherapy affects Treg cells remain elusive. In this study, we first analyzed Treg cell subsets in peripheral blood samples from 40 nonsmall cell lung cancer (NSCLC) patients and 20 healthy donors. Treg cells, specifically activated Treg cell subset, significantly increased in patients with NSCLC. Compared to nonsuppressive Treg cells, activated Treg cells expressed higher level of CD39 and predominantly produced inhibitory cytokines. In vitro assay showed that docetaxel reduced all three subsets of Treg cells. More importantly, we found docetaxel-based chemotherapy significantly decreased all three Treg subsets after 4 cycles of treatment in 17 NSCLC patients. Taken together, this study revealed dynamic changes of various Treg cell subsets in NSCLC patients before and after chemotherapy, providing activated Treg cells as a potential target for chemotherapy.
    Full-text · Article · Apr 2014 · Research Journal of Immunology
Show more